Joseph Holoshitz, MD
University of Michigan
Dr. Holoshitz's laboratory has made significant advances in understanding a genetic risk factor of rheumatoid arthritis (RA) called the shared epitope. Today, he is building on that initial research to study new chemical compounds that could potentially inhibit the shared epitope's effect on rheumatoid arthritis patients. This knowledge could lead to new treatments for patients like Laura, with clinical trials possibly starting as early as 2020. Read More >>